World number two and five-times Grand Slam champion Iga Swiatek has accepted a one-month suspension after testing positive for banned substance trimetazidine (TMZ), the International Tennis Integrity Agency said on Thursday (Nov 28).

Swiatek tested positive in an out-of-competition sample in August but the ITIA, which runs tennis's anti-doping programme, accepted that it was caused by contamination of her medication melatonin, which was manufactured and sold over the counter in her native Poland.

Swiatek said she had been taking it for jet lag and sleep issues and as there was no significant fault or negligence, the ITIA ruled it was "the lowest end of the range" and offered the reigning French Open champion a one-month suspension which the 23-year-old accepted.

"The player was provisionally suspended from Sept. 12 until Oct. 4, missing three tournaments, which counts towards the sanction, leaving eight days remaining," the ITIA said in a statement."

She also forfeited prize money from the Cincinnati Open, the tournament directly following the test.

Related

---